Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C chemokines.
Eosinophils are the predominant cell type recruited in inflammatory reactions in response to allergen challenge. The mechanisms of selective eosinophil recruitment in allergic reactions are not fully elucidated. In this study, the ability of several C-C chemokines to induce transendothelial migration (TEM) of eosinophils in vitro was assessed. Eotaxin, eotaxin-2, monocyte chemotactic protein (MCP)-4, and RANTES induced eosinophil TEM across unstimulated human umbilical vein endothelial cells (HUVEC) in a concentration-dependent manner with the following rank order of potency: eotaxin approximately eotaxin-2 > MCP-4 approximately RANTES. The maximal response induced by eotaxin or eotaxin-2 exceeded that of RANTES or MCP-4. Preincubation of eosinophils with anti-CCR3 Ab (7B11) completely blocked eosinophil TEM induced by eotaxin, MCP-4, and RANTES. Activation of endothelial cells with IL-1beta or TNF-alpha induced concentration-dependent migration of eosinophils, which was enhanced synergistically in the presence of eotaxin and RANTES. Anti-CCR3 also inhibited eotaxin-induced eosinophil TEM across TNF-alpha-stimulated HUVEC. The ability of eosinophil-active cytokines to potentiate eosinophil TEM was assessed by investigating eotaxin or RANTES-induced eosinophil TEM across resting and IL-1beta-stimulated HUVEC in the presence or absence of IL-5. The results showed synergy between IL-5 and the chemokines but not between IL-5 and the endothelial activator IL-1beta. Our data suggest that eotaxin, eotaxin-2, MCP-4, and RANTES induce eosinophil TEM via CCR3 with varied potency and efficacy. Activation of HUVEC by IL-1beta or TNF-alpha or priming of eosinophils by IL-5 both promote CCR3-dependent migration of eosinophils from the vasculature in conjunction with CCR3-active chemokines.
Shahabuddin
S
S
Department of Medicine, Division of Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
Ponath
P
P
Schleimer
R P
RP
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002465:Cell Movement / Q000276:immunology*; D002478:Cells, Cultured; D054413:Chemokine CCL11; D054423:Chemokine CCL24; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors / Q000502:physiology; D019742:Chemokines, CC / Q000037:antagonists & inhibitors / Q000502:physiology*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000502:physiology*; D004306:Dose-Response Relationship, Immunologic; D019040:E-Selectin / Q000276:immunology; D004730:Endothelium, Vascular / Q000166:cytology / Q000276:immunology* / Q000378:metabolism*; D004804:Eosinophils / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D039041:Integrin alpha4beta1; D016023:Integrins / Q000276:immunology; D007375:Interleukin-1 / Q000494:pharmacology; D015848:Interleukin-5 / Q000502:physiology*; D018945:Monocyte Chemoattractant Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D054397:Receptors, CCR3; D019707:Receptors, Chemokine / Q000276:immunology / Q000502:physiology; D016201:Receptors, Lymphocyte Homing / Q000276:immunology; D014471:Umbilical Veins
D000911:Antibodies, Monoclonal; C515456:CCL11 protein, human; C099677:CCL13 protein, human; C515484:CCL24 protein, human; C515350:CCR3 protein, human; D054413:Chemokine CCL11; D054423:Chemokine CCL24; D018946:Chemokine CCL5; D019742:Chemokines, CC; D016207:Cytokines; D019040:E-Selectin; D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D039041:Integrin alpha4beta1; D016023:Integrins; D007375:Interleukin-1; D015848:Interleukin-5; D018945:Monocyte Chemoattractant Proteins; D054397:Receptors, CCR3; D019707:Receptors, Chemokine; D016201:Receptors, Lymphocyte Homing